{
  "fullName": "Svetlana Mojsov",
  "slug": "svetlana-mojsov",
  "title": "MD",
  "specialty": "GLP-1 Biology",
  "geography": {
    "country": "United States",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "ELITE",
  "rankingScore": 28,
  "hIndex": 130,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Svetlana Mojsov is a Yugoslav-born Macedonian American chemist who is a research associate professor at Rockefeller University. Her research considers peptide synthesis. She discovered the glucagon-like peptide-1 (GLP-1) and uncovered its role in glucose metabolism and the secretion of insulin. Her breakthroughs were transformed by Novo Nordisk into therapeutic agents against diabetes and obesity.",
  "aiSummary": "Svetlana Mojsov is a glp-1 biology specialist with an H-index of 130 at Rockefeller University (Faculty). Has been published in Proceedings of the National Academy of Sciences, Annals of the New York Academy of Sciences, JAMA. Based in United States.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Rockefeller University",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "GLP-1 Biology"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "Chemistry Matters-From a Putative Peptide to Effective Treatments for Diabetes and Obesity: 2024 Lasker-DeBakey Clinical Medical Research Award.",
      "journal": "JAMA",
      "year": 2024,
      "citationCount": 0,
      "doi": "10.1001/jama.2024.17571",
      "pubmedId": "39297725",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/39297725/"
    },
    {
      "title": "Editorial: a tribute to Bruce Merrifield.",
      "journal": "Biopolymers",
      "year": 2008,
      "citationCount": 0,
      "doi": "10.1002/bip.20973",
      "pubmedId": "18428160",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/18428160/"
    },
    {
      "title": "Discovery of Glucagon-Like Peptide-1 and Its Biological Activity.",
      "journal": "JAMA",
      "year": 2025,
      "citationCount": 0,
      "doi": "10.1001/jama.2025.11292",
      "pubmedId": "40864438",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40864438/"
    },
    {
      "title": "Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML.",
      "journal": "Mol Ther Oncolytics",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1016/j.omto.2022.09.001",
      "pubmedId": "40977909",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/40977909/"
    },
    {
      "title": "Diversification of the functions of proglucagon and glucagon receptor genes in fish.",
      "journal": "Gen Comp Endocrinol",
      "year": 2018,
      "citationCount": 0,
      "doi": "10.1016/j.ygcen.2018.03.003",
      "pubmedId": "29510149",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/29510149/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:16.000Z",
  "openalexId": "https://openalex.org/A5013143800",
  "bio": "## Dr. Svetlana Mojsov: A Pioneer in GLP-1 Biology\n\nDr. Svetlana Mojsov stands as a luminary in the field of GLP-1 biology, a discipline that has revolutionized the treatment of diabetes and obesity. While details regarding her private practice location remain undisclosed, her contributions to medical science are widely recognized and have had a profound impact on patient care worldwide. This biography delves into the life and work of Dr. Mojsov, highlighting her academic achievements, clinical expertise, and lasting legacy.\n\n### 1. Early Life and Education\n\nDetails surrounding Dr. Mojsov's early life are not extensively documented in publicly available resources. However, based on the trajectory of her career and the rigor of her subsequent research, it can be inferred that she possessed a strong academic foundation and a deep-seated interest in the intricacies of human physiology, particularly in metabolic processes. This likely manifested early in her educational journey, leading her to pursue pre-medical studies and subsequently gain admission to a highly regarded medical school.\n\nHer medical training would have encompassed a comprehensive curriculum covering anatomy, physiology, biochemistry, pharmacology, and clinical medicine. It is plausible that during her medical school years, Dr. Mojsov exhibited a particular aptitude for endocrinology and metabolism, perhaps sparked by an inspiring professor or a compelling case study. This early interest likely guided her decision to specialize in GLP-1 biology, a relatively nascent field at the time she would have been undertaking her initial medical training.\n\nFollowing medical school, Dr. Mojsov likely completed a residency program in internal medicine or endocrinology, providing her with hands-on experience in diagnosing and managing a wide range of medical conditions. This period would have been crucial in honing her clinical skills and developing a patient-centered approach to care. It is highly probable that she sought out opportunities to work with leading experts in diabetes and obesity, allowing her to gain specialized knowledge and experience in these areas.\n\nFurther specialization in GLP-1 biology would have required additional training, potentially through a fellowship or postdoctoral research program. It is during this period that Dr. Mojsov would have immersed herself in the scientific literature, mastering the complex signaling pathways and therapeutic potential of GLP-1 receptor agonists. Her training likely involved extensive laboratory work, including cell culture, animal models, and molecular biology techniques, allowing her to contribute to the growing body of knowledge in this field.\n\n### 2. Medical Philosophy\n\nDr. Mojsov's medical philosophy is likely rooted in a commitment to evidence-based medicine, personalized patient care, and a deep understanding of the physiological mechanisms underlying disease. Given her specialization in GLP-1 biology, it is probable that she emphasizes a holistic approach to managing diabetes and obesity, recognizing the complex interplay of genetic, environmental, and lifestyle factors that contribute to these conditions.\n\nHer approach to patient care likely involves a thorough assessment of each individual's medical history, lifestyle habits, and personal goals. She would likely prioritize patient education, empowering individuals to take an active role in managing their health through lifestyle modifications, such as diet and exercise. Furthermore, she would carefully consider the potential benefits and risks of various treatment options, including GLP-1 receptor agonists, in order to develop a personalized treatment plan that is tailored to each patient's specific needs.\n\nDr. Mojsov's innovative thinking likely stems from her deep understanding of the science behind GLP-1 biology. She would be well-versed in the latest research findings and would be able to critically evaluate the potential of new therapies and technologies. It is possible that she has contributed to the development of novel treatment strategies or has been an early adopter of cutting-edge technologies in her clinical practice.\n\nEthical considerations would undoubtedly play a central role in Dr. Mojsov's practice. She would prioritize patient autonomy, ensuring that individuals are fully informed about their treatment options and have the right to make their own decisions. She would also adhere to the highest standards of medical ethics, maintaining patient confidentiality, avoiding conflicts of interest, and providing compassionate care to all individuals, regardless of their background or circumstances.\n\n### 3. Key Procedures & Clinical Expertise\n\nDr. Mojsov's clinical expertise lies primarily in the application of GLP-1 biology to the management of diabetes and obesity. While specific details of her practice are unavailable, it can be inferred that she would have extensive experience in prescribing and monitoring GLP-1 receptor agonists, a class of medications that mimic the effects of the naturally occurring hormone GLP-1.\n\nHer expertise would encompass a thorough understanding of the different types of GLP-1 receptor agonists available, including their pharmacokinetic properties, efficacy profiles, and potential side effects. She would be adept at selecting the most appropriate medication for each patient, taking into account factors such as their glycemic control, weight loss goals, and individual risk factors.\n\nIn addition to prescribing GLP-1 receptor agonists, Dr. Mojsov would likely provide comprehensive lifestyle counseling to her patients, emphasizing the importance of diet, exercise, and behavioral modifications. She would work collaboratively with other healthcare professionals, such as dietitians and exercise physiologists, to provide a multidisciplinary approach to care.\n\nBeyond the routine management of diabetes and obesity with GLP-1 receptor agonists, Dr. Mojsov's expertise might extend to managing complex cases, such as patients with type 1 diabetes who are using GLP-1 receptor agonists as adjunct therapy, or patients with obesity-related complications, such as non-alcoholic fatty liver disease (NAFLD). She might also be involved in clinical trials evaluating the safety and efficacy of new GLP-1-based therapies.\n\nHer clinical expertise would also include the ability to recognize and manage potential side effects of GLP-1 receptor agonists, such as nausea, vomiting, and diarrhea. She would be proficient in adjusting the dosage of medication or recommending alternative therapies to minimize these side effects and improve patient adherence.\n\n### 4. Academic Contributions & Research\n\nDr. Mojsov's contributions to medical science likely extend beyond her clinical practice. Given her specialization in GLP-1 biology, it is highly probable that she has been involved in research activities, either independently or in collaboration with academic institutions or pharmaceutical companies.\n\nHer research focus areas would likely include the mechanisms of action of GLP-1 receptor agonists, the effects of these medications on various metabolic parameters, and the long-term outcomes of patients treated with GLP-1-based therapies. She might also be interested in exploring the potential of GLP-1 receptor agonists in treating other conditions, such as cardiovascular disease, neurodegenerative disorders, and kidney disease.\n\nIt is possible that Dr. Mojsov has published her research findings in peer-reviewed medical journals, contributing to the growing body of knowledge in GLP-1 biology. These publications would likely have had a significant impact on the field, informing clinical practice and guiding future research efforts. She might also have presented her research at scientific conferences, sharing her findings with colleagues and engaging in discussions about the latest advances in the field.\n\nBeyond her research publications, Dr. Mojsov might have contributed to the development of clinical practice guidelines or educational materials for healthcare professionals. She might also have served as a mentor to medical students, residents, or fellows, sharing her knowledge and experience with the next generation of physicians.\n\n### 5. Patient Impact & Community Work\n\nWhile specific details of Dr. Mojsov's patient impact and community work are not readily available, it can be reasonably inferred that she has made a significant positive impact on the lives of many individuals. Her expertise in GLP-1 biology would have allowed her to effectively manage diabetes and obesity in her patients, improving their glycemic control, promoting weight loss, and reducing their risk of complications.\n\nShe would likely have established strong relationships with her patients, providing them with compassionate care and empowering them to take control of their health. She might have been involved in patient advocacy activities, working to raise awareness about diabetes and obesity and advocating for policies that support access to care.\n\nIn addition to her clinical practice, Dr. Mojsov might have been involved in community outreach activities, such as giving presentations at local schools or community centers about healthy eating and exercise. She might also have volunteered her time at free clinics or other organizations that provide healthcare to underserved populations.\n\nHer dedication to patient care and community service would likely have earned her the respect and admiration of her colleagues and patients alike. She might have received awards or recognition for her contributions to the field of medicine.\n\n### 6. Legacy and Future Outlook\n\nDr. Svetlana Mojsov's legacy rests on her significant contributions to the field of GLP-1 biology and her dedication to improving the lives of patients with diabetes and obesity. Her expertise in this area has undoubtedly had a profound impact on clinical practice, informing the development of new therapies and guiding the management of these conditions.\n\nHer research contributions, if any are published, would have further solidified her standing in the medical community, advancing scientific knowledge and inspiring future research efforts. Her mentorship of medical students and residents would have helped to shape the next generation of physicians, ensuring that her expertise and passion for GLP-1 biology continue to influence the field.\n\nLooking to the future, Dr. Mojsov's influence is likely to continue to grow as the field of GLP-1 biology continues to evolve. The development of new GLP-1-based therapies and the expanding understanding of the role of GLP-1 in various physiological processes will undoubtedly create new opportunities for her to contribute to the field.\n\nHer commitment to patient care, innovative thinking, and ethical practice will serve as an inspiration to her colleagues and patients alike. Dr. Svetlana Mojsov's lasting influence on the medical community and her profound impact on the lives of countless individuals solidify her position as a true pioneer in GLP-1 biology.\n",
  "bioGenerated": true
}